쎌바이오텍 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 윤영옥, was filed 09 Dec 2025.
쎌바이오텍: what insiders have been doing
Every trade that managers of 쎌바이오텍 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. In the past year (1 November 2025 to 1 November 2026), 3 filings came from 2 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 2 purchases. The totals exclude 2 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 1 board member.
The last insider purchase was made public on 9 December 2025, 336 days ago.
Compared with its exchange (2,655 companies, median 7 filings), a count of 3 filings is below the norm. The full history, which starts in 2021, counts 4 purchases against 3 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleTransparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- ●Executives0DART
- 16,261 sharesShareKRXDART:20251209000291Canonical exit: 9 Mar 2026 (T+90)
- 43,739 sharesShareKRXDART:20251128001878Canonical exit: 26 Feb 2026 (T+90)
- ●Executives0DART
- 3,836 sharesShareKRXDART:20250206000535
- 155,521 sharesKRXDART:20240207000565
- 10,556 sharesKRXDART:20230406000972
- ●Executives0DART
- 23,953 sharesKRXDART:20221130002042Canonical exit: 1 Mar 2023 (T+90)
- 74,798 sharesKRXDART:20220610000414Canonical exit: 8 Sept 2022 (T+90)
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
15 of 15 declarations
About 쎌바이오텍
Cell Biotech is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biopharmaceutical solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
